39753-81-6

Usage

Uses

Used in Pharmaceutical Industry:
(4-NITRO-PYRAZOL-1-YL)-ACETIC ACID ETHYL ESTER is used as a building block for the synthesis of pharmaceuticals, as it can be used to create new compounds with biological activity. Its potential applications in medicinal chemistry make it a valuable component in the development of new drugs.
Used in Agrochemical Industry:
(4-NITRO-PYRAZOL-1-YL)-ACETIC ACID ETHYL ESTER is also used as a building block in the synthesis of agrochemicals, contributing to the development of new compounds with potential applications in agriculture, such as pesticides or herbicides. Its versatility in chemical synthesis allows for the creation of various agrochemical products.

Upstream product

• 2075-46-9 4-nitro-1H-pyrazole 
• 105-36-2 ethyl bromoacetate 
• 637-80-9 ethyl 2-hydrazinylacetate 
• 181294-57-5 β-formyl-β-nitroenamine 

Downstream Products

• 1152853-30-9 2-(4-amino-1H-pyrazol-1-yl)-N-methylacetamide 
• 1339619-68-9 N-methyl-2-(4-nitro-1H-pyrazol-1-yl)acetamide 
• 6645-69-8 2-(4-nitro-1H-pyrazol-1-yl)acetic acid 
• 1152841-53-6 ethyl 2-(4-amino-1H-pyrazol-1-yl)acetate 

Relevant academic research and scientific papers

INHIBITORS OF NECROPTOSIS

This invention relates to compounds of Formula (I) and salts, solvates, prodrugs, tautomers, N-oxides, stereoisomers, polymorphs and physiologically functional derivatives thereof. Also disclosed are methods of use of Formula (I), including in the inhibition of necroptosis and treatment of associated diseases, conditions and/or disorders.

JAK INHIBITORS

Described herein are Janus kinase (JAK) inhibitors and methods of utilizing JAK inhibitors in the treatment of diseases, disorders or conditions. Also described herein are pharmaceutical compositions containing such compounds.

JAK INHIBITORS

Described herein are Janus kinase (JAK) inhibitors and methods of utilizing JAK inhibitors in the treatment of diseases, disorders or conditions. Also described herein are pharmaceutical compositions containing such compounds.

Five-And-Six-Membered Heterocyclic Compound, And Preparation Method, Pharmaceutical Composition And Use Thereof

A five-and-six-membered heterocyclic compound as represented by general formula I, pharmaceutically acceptable salt, metabolite, metabolic precursors or drug precursors thereof, preparation method, pharmaceutical composition, and use thereof; the five-and-six-membered heterocyclic compound has activity as a Janus kinase (JAK) inhibitor, and can be used to prepare drugs for treating diseases caused by the abnormal activity of kinase, such as cell proliferation diseases like cancer.

New synthetic equivalent of nitromalonaldehyde treatable in organic media

β-Nitroenamines having a formyl group at the β-position behave as the synthetic equivalent of unstable nitromalonaldehyde, which is a useful synthon for syntheses of versatile nitro compounds. High solubility of the nitroenamines into general organic solv

A GENERAL METHOD OF PREPARATION OF N-DIFORMYLMETHYLAZOLES AND CYCLOIMONIUM DIFORMYL METHYLIDES

Formylation of easily accessible heteroarylacetic acids (R-CH2COOH, R = imidazole, pyrazole, tetrazole, pyridine) afforded in high yields the corresponding trimethinium salts (R-C(=CH-N(CH3)2)CH=N(CH3)2)(n+)*nX(-) which on alkaline hydrolysis were converted into N-diformylmethylazoles R-C(CHO)=CH-OH.Their quaternization gave cycloimonium diformyl methylides.